Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...

GPP can be triggered by the initiation and withdrawal of various medications, in particular the withdrawal of corticosteroids, and by infections, stress, and other conditions. 1,5,6,10 Patients with a ...

An international consensus statement on generalized pustular psoriasis (GPP) from the International Psoriasis Council (IPC) includes the recommendation that considerations such as body surface area ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Patients with generalized pustular psoriasis had a reduction in pustules and increased skin clearance ...

Please provide your email address to receive an email when new articles are posted on . Spevigo (spesolimab) reduced the risk for generalized pustular psoriasis flares by 84% over 48 weeks. Spevigo’s ...

In 1910, Leo Ritter von Zumbusch meticulously detailed the clinical course of "psoriasis pustulosa generalisata" (referred to herein as generalized pustular psoriasis, GPP) in a brother and sister, ...

A retrospective US claims study found that adults with generalized pustular psoriasis (GPP) had significantly more healthcare visits and costs than patients with plaque psoriasis alone. Researchers ...

The FDA has approved the monoclonal antibody spesolimab (Spevigo) as the first treatment for generalized pustular psoriasis (GPP), Boehringer Ingelheim announced. The approval stipulates use of the ...

Spevigo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 signaling. The Food and Drug Administration (FDA) has approved Spevigo ® (spesolimab-sbzo) for the treatment ...

Credit: Boehringer Ingelheim. The approval was based on data from the phase 2 Effisayil-2 study which included patients 12 years of age and older and weighing at least 40kg with a history of at least ...

INGELHEIM, Germany--(BUSINESS WIRE)--Today, at the 25 th World Congress of Dermatology (WCD), Boehringer Ingelheim presented new late-breaking data from the EFFISAYIL™ 2 trial showing that spesolimab ...

BRACKNELL, England--(BUSINESS WIRE)--Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II Effisayil TM 1 trial, which ...